ArticleEye (London, England)2026
Patient-reported outcome measures 1 year after conjunctival melanoma treatment using EORTC QLQ-C30 and QLQ-OPT30 questionnaires.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate patient-reported outcome measures (PROMs) in biopsy-confirmed and treated conjunctival melanoma.
methodsRetrospective, cross-sectional observational case series assessing PROMs 1 year after initial treatment. A total of 13 consecutive patients who underwent excision of newly diagnosed conjunctival melanoma between June and December 2023 in a single UK specialized tertiary center met the inclusion criteria. Of these, 11 patients (85%) completed the EORTC QLQ-C30 (Quality of Life of Cancer Patients) and QLQ-OPT30 (Quality of Life of Ophthalmic Cancer Patients) questionnaires. The 60 items assessed general health, ocular symptoms, functional status, psychosocial impacts, overall quality of life and health within the last week. Responses were analysed.
resultsMean scores across the 58 items ranged from 1.00 to 2.18/4 ('not at all 'to 'a little'), indicating an overall mild impact. Patients were slightly limited in activities of daily living but more restricted in pursuing hobbies and social activities, which most did not attribute to their eyesight. Patients reported some symptoms of depression and worry, both generally and related to their health. Common ocular symptoms included: dry eye, watering, difficulty driving in the dark and difficulty judging distances. Overall health in the last week was rated 4.91/7 and overall quality of life was 5.18/7.
conclusionsThere is a paucity of research exploring quality of life in treated conjunctival melanoma. These findings can help inform patients and clinicians about potential long-term symptoms, functional difficulties and psychological effects, thereby managing expectations. Consequently, further endeavours can be directed to better support patients with conjunctival melanoma.
Identifiers
42816527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.